Instruction 1(b)

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HILZINGER KURT J					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [ OTLK ]						(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner						
														X Directo				·
(Last)	`	irst) IERAPEUTICS,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/05/2022										Officer (give title below)		Other (s below)	pecify	
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320																		
- I STANDER TO SETTE 320				4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X Form f	iled by One	Repo	orting Person	n
ISELIN	N.	J	08830												Form filed by More than One Re Person			orting
(City)	(S	tate)	(Zip)															
		Tab	le I - Non	-Deriv	ative	e Se	curities	s Ac	quired, D	ispos	ed o	f, or Be	neficial	y Owned	l .			
1. Title of Security (Instr. 3)  2. Trans. Date (Month/I				ction 2A. Deemed Execution Date, if any (Month/Day/Year			Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)				Benefici	es ally Following	Form (D) or	Ownership orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	Am	ount	(A) or (D)	Price	Transaci (Instr. 3	tion(s)			111311. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security Or Exercise (Month/Day/Year) Execution Date,			ate, T	ransaction of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				c	ode	v	(A)	(D)	Date Exercisable	Expira Date	tion	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.25	10/05/2022			A		57,598		(1)	10/05/2	2032	Common Stock	57,598	\$0.00	57,598	3	D	

## **Explanation of Responses:**

1. The options were granted under the 2015 Plan in lieu of \$60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

## Remarks:

/s/ Lawrence A. Kenyon, Attorney-in-Fact

10/07/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.